MALAT1 and breast cancer: Another panel, combining four lncRNAs (UCA1-201, HOTAIR, HYMA1, and MALAT1) showed a sensitivity of 93.3% and specificity of 96.7% and was able to effectively distinguish NMIBC patients from BC patients [86].